N4 Pharma PLC Exercise of Options (3667Y)
08 September 2020 - 12:40PM
UK Regulatory
TIDMN4P
RNS Number : 3667Y
N4 Pharma PLC
08 September 2020
8 September 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Exercise of Options
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, confirms that 1,350,000 Ordinary Shares of 0.4 pence
each ("Ordinary Shares") have been issued by the Company pursuant
to an exercise of options over Ordinary Shares for total
consideration of GBP37,800.
Application has been made for the 1,350,000 new Ordinary Shares
to be admitted to trading on AIM ("Admission"), which is expected
to occur at 8.00 a.m. on or around 14 September 2020. The new
Ordinary Shares will rank pari passu with the existing Ordinary
Shares. The Company does not hold any Ordinary Shares in
treasury.
Following Admission and for the purposes of the Disclosure
Guidance and Transparency Rules, the Company's total issued share
capital will consist of 156,080,349 Ordinary Shares. Shareholders
may use this figure as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the issued share
capital of the Company.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ALSKKFBNKBKDPCK
(END) Dow Jones Newswires
September 08, 2020 06:40 ET (10:40 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024